From valsartan to Lunapharm what are the consequences?
THERAPY FROM A CRITICAL VIEWPOINT
New indication rivaroxaban (XARELTO) for stable coronary heart disease and peripheral arterial disease
a-t READERS QUESTIONS AND COMMENTS
Aluminium in vaccines
Antidepressant agomelatine (VALDOXAN) risk mitigation measures are not followed
ALZHEIMERs drugs no longer reimbursed in France free article
Supply shortage expiry dates of epinephrine auto-injectors extended
Diabetes omega-3 fatty acids for cardiovascular prevention?
Vacuum wound treatment data under lock and key
Diabetes mellitus: FOURNIER gangrene with SGLT-2 inhibitors
Daclizumab: encephalitis even months after discontinuation
Restrictions of use of IBEROGAST 10 years too late
e a-t ON THE INTERNET
Flu vaccines 2018/19
© 2018 arznei-telegramm